



## DISCOVERY LABORATORIES, INC.

### **Discovery Laboratories Announces Conference Call and Webcast to Update Progress of Phase 3 Clinical Trials for Respiratory Distress Syndrome in Premature Infants**

**Doylestown, PA – June 3, 2003 – Discovery Laboratories, Inc. (Nasdaq: DSCO)**, a late-stage specialty biopharmaceutical company developing its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory diseases, announces a conference call to be held Thursday, June 5<sup>th</sup> at 8:30 AM EDT. Management will update progress of the Company's Phase 3 Clinical Trials for Respiratory Distress Syndrome in Premature Infants.

This audio webcast will be available to shareholders and interested parties through a live broadcast on the Internet at <http://audioevent.mshow.com/1007370/> and [www.discoverylabs.com](http://www.discoverylabs.com). It is recommended that participants log onto one of these sites at least 15 minutes prior to the call. The Internet broadcast will be available for up to 30 days after the call at both website addresses. Please submit questions in advance to [dSCO@focuspartners.com](mailto:dSCO@focuspartners.com).

#### **About Discovery Laboratories, Inc.**

Discovery Laboratories, Inc. is a specialty biopharmaceutical company developing its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory diseases including Respiratory Distress Syndromes, Acute Lung Injury (ALI), asthma, Chronic Obstructive Pulmonary Disease (COPD), and upper airway disorders. Discovery's surfactant technology produces an engineered version of natural human lung surfactant that is designed to precisely mimic the essential properties of human lung surfactant. Discovery believes that through its surfactant technology, pulmonary surfactants have the potential, for the first time, to be developed into a series of respiratory therapies for hospitalized and ambulatory patients. Surfaxin<sup>®</sup>, Discovery's lead product, is in three Phase 3 and two Phase 2 clinical trials for critical care patients with life-threatening respiratory disorders where there are few or no approved therapies available. Discovery's first aerosol surfactant product is positioned to enter clinical trials for hospital patients with severe asthma or acute lung injury. Discovery has a commercialization alliance with Quintiles Transnational Corp. and a strategic alliance with Laboratorios del Dr. Esteve S.A.

Interested parties can receive corporate updates by sending their email addresses to [dSCO@focuspartners.com](mailto:dSCO@focuspartners.com). More information about Discovery Laboratories is available on the Company's website at [www.discoverylabs.com](http://www.discoverylabs.com).

#### **Contacts**

John Cooper  
CFO/SVP  
215-340-4699  
[ir@discoverylabs.com](mailto:ir@discoverylabs.com)

FOCUS Partners LLC  
Harvey Goralnick/David Zazoff  
212-752-9445  
[dSCO@focuspartners.com](mailto:dSCO@focuspartners.com)

###